Skip to main content

mat2a inhibitor bg-89894

Generic: MAT2A Inhibitor BG-89894

mat2a inhibitor bg-89894: 2 clinical trials tracked.

mat2a inhibitor bg-89894 evidence translation

What we can confirm

2 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about mat2a inhibitor bg-89894, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence0 indications · 1 study sponsors

Related indications

No linked indication is available.

Clinical Trials (2)

A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors

NCT06589596·Phase 1·ONC
Recruiting

Primary endpoint: Phase 1a: Number of Participants with Adverse Events and Serious Adverse Events

Interventionalopen525 targetStarted 2025-01Completion 2027-0950 sites · Australia, Brazil, China, United StatesBeOne Medicines

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-89894 (SYH2039) Tablets in Patients With Advanced Solid Tumors

NCT06568614·Phase 1·ONC
Terminated

Primary endpoint: Phase 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

Interventionalopen29 targetStarted 2024-10Completion 2026-0420 sites · Australia, China, United StatesBeOne Medicines